NRx Pharmaceuticals (NRXP) Expected to Announce Quarterly Earnings on Friday

NRx Pharmaceuticals (NASDAQ:NRXP) will likely be releasing its earnings data before the market opens on Friday, April 4th. Analysts expect NRx Pharmaceuticals to post earnings of ($0.20) per share for the quarter.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NRx Pharmaceuticals Price Performance

Shares of NRx Pharmaceuticals stock opened at $2.07 on Friday. The company’s fifty day simple moving average is $2.61 and its two-hundred day simple moving average is $2.04. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01. The firm has a market cap of $35.02 million, a PE ratio of -0.97 and a beta of 1.22.

Analysts Set New Price Targets

A number of analysts recently commented on NRXP shares. Ascendiant Capital Markets raised their price target on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. Finally, D. Boral Capital reiterated a “buy” rating and set a $31.00 price target on shares of NRx Pharmaceuticals in a research report on Monday.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.